/NEWS / Articles




Articles - Articles

  • Personalised medicine group helps shape new IVD rules

    The European Parliament and European Council have reached a political agreement on the Medical Device Regulation and the In Vitro Medical Device Regulation.  The discussions have been ongoing since 2012.  The Brussels-based European Alliance for Personalised Medicine (EAPM) welcomes the inclusion of many suggestions and recommendations it has made during the process, writes European Alliance for Personalised Medicine (EAPM) Executive Director Denis Horgan.

  • Genetic testing not yet perfect - but it’s benefits are real
    In this fast-moving world of science, especially in medicine, genetic testing is seen by many to have a high potential value.
    Over in the United States, President Obama began a $215 million precision medicine initiative early in 2015, defined it as an approach that accounts for “individual differences in people’s genes, environments and lifestyles”.

  • Press Release: Top-level conference ‘takes stock’ of personalised medicine

    Brussels, 4 April: The theme of the European Alliance for Personalised Medicine’s fourth annual Presidency conference, during the Dutch Presidency of the EU, will be "Taking Stock: Where we are now and the necessary next steps" on April 5th/6th.

    The event will bring together key decision makers and thought leaders in the exciting new arena of personalised medicine.

  • Rare diseases: looking better in genes

    February 28 is Rare Disease Day. The European Commission defines rare diseases as any disease affecting fewer than five people in 10,000. Its figures estimate that, today in the EU, 5-8000 distinct rare diseases affect 6-8% of the population – that’s between 27-36 million people. The EU executive adds that: “The number of patients affected by each particular rare disease is, by definition, limited. There are diseases which may affect only very few patients, in particular in smaller Member States. This, together with the fragmentation of knowledge across the EU, makes rare diseases a primary example of where working at European level is both necessary and highly beneficial.” 

  • Almost there: Gene technology in the health arena

    Understanding of genomics has increased substantially since the year 2000, by which point the majority of the genome had been sequenced as part of the Human Genome Project. In April 2003, scientists announced that they had completed the Project, which was tasked with putting together a list of the three billion letters of genetic code that make up human DNA. (The original idea was to develop a resource - a reference genome representing humanity.)

  • EU draft health document has stakeholders gathering to respond

    Earlier this week, the European Commission and its independent Expert Panel on effective ways of investing in health launched a public consultation on its preliminary opinion, with results due in from stakeholders by 16 December. 

    The opinion explores the implications of Disruptive Innovation for health and health care in Europe.

  • Time to get clinical over much-needed guidelines

    Treating patients is often not an easy task – difficult decisions need to be made, often in the face of uncertainty.

    But clinical guidelines exist to help, including recommendations aimed at optimising patient care. They are based on existing evidence, systematically reviewed, but because there are so many, it can even then often be difficult to assess which are the best.

  • People’s’ health-data website launches in Europe

    Wednesday 25 November saw the launch of a new website that aims to run ‘citizen-owned personal data cooperatives’ to protect personal health data while allowing its use for vital health research. 

    The MIDATA cooperatives will enable patients to gather all their different data in one secure place, allowing them to decide to share it with physicians or to participate in research.

[ previous | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | next ] pages: 14

» Back to categories